# US 2024/0002797 A1 · Methods of cell culture for adoptive cell therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002797 A1
- Document ID: US20240002797A1
- Status: Published application
- Kind: A1
- Application number: 18/198,708
- Filed: 2023-05-17
- Published: 2024-01-04
- Earliest claimed: 2009-12-08
- Assignees: Wilson Wolf Manufacturing
- Applicants: Wilson Wolf Manufacturing
- Inventors: Juan F. Vera; Cliona M. Rooney; Ann M. Leen; John R. Wilson
- Web page: https://patentgrep.com/patent/US20240002797A1

## CPC

- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- A61K 9/5068: {Cell membranes or bacterial membranes enclosing drugs (liposomes with additional exogenous lipids A61K9/127)}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/416: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 40/418: {Antigens related to induction of tolerance to non-self}
- A61K 40/4274: {Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]}
- A61K 40/46: Viral antigens
- A61K 48/0033: {the non-active part being non-polymeric}
- A61K 51/08: Peptides, e.g. proteins {, carriers being peptides, polyamino acids, proteins}
- C12N 5/0636: {T lymphocytes}
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- A61K 40/50: characterised by the use of allogeneic cells
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/55527: {Interleukins}
- A61K 2039/55533: {IL-2}
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- A61K 2239/58: Prostate
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 2319/03: containing a transmembrane segment
- C12M 23/24: {Gas permeable parts}
- C12N 2310/16: Aptamers
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N 2502/11: blood or immune system cells
- C12N 2502/1107: B cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}

## Abstract

Production and use of novel therapeutic cells, called T-Vehicles, in the allogeneic Adoptive Cell Therapy setting allows a wide range of therapeutic benefits to accrue with minimal or no risk of GVHD. T-Vehicles are created from donor T cells that are altered to contain therapeutic attributes that do not include their native antigen receptors and can deliver therapeutic benefits irrelevant of their native antigen specificity. T-Vehicles can possess highly restricted native antigen specificity that renders them unable to recognize antigens present on normal cells and incapable of initiating GVHD, making them ideal transport vehicles to deliver various therapeutic attributes in vivo. In essence, production and use of T-Vehicles is a paradigm shift that opens the door to therapeutic application of T cells in ways not previously contemplated, independent of whether or not there is an HLA match between the donor and the recipient.

## Claims

### Claim 1

A method of antigen specific cell production, comprising:
adding medium, EBV-CTLs, and irradiated autologous EBV-LCLs into a cell culture device having a gas permeable growth surface, wherein said EBV-CTLs are at a surface density of 5×105 cells/cm2 of gas permeable growth surface and said irradiated autologous EBV-LCLs are at a EBV-CTL:EBV-LCL ratio of 4:1, and wherein the medium volume to gas permeable growth surface area ratio is at least 3 mL/cm2; and
allowing the EBV-CTLs to expand to a quantity beyond 5×106 cells/cm2 of gas permeable growth surface over a period of time without adding new media.

### Claim 2 (depends on 1)

The method of claim 1 wherein the period of time is 3 days.

### Claim 3 (depends on 1)

The method of claim 1 wherein the ratio of EBV-CTL:EBV-LCL is 8:1.

### Claim 4 (depends on 1)

The method of claim 1 wherein the ratio of EBV-CTL:EBV-LCL is 2:1.

### Claim 5 (depends on 1)

The method of claim 1 wherein the ratio of EBV-CTL:EBV-LCL is 1:1.

### Claim 6 (depends on 1)

The method of claim 1 wherein the ratio of EBV-CTL:EBV-LCL is 1:2.

### Claim 7 (depends on 1)

The method of claim 1 wherein the ratio of EBV-CTL:EBV-LCL is 1:4.

### Claim 8 (depends on 1)

The method of claim 1 wherein the ratio of EBV-CTL:EBV-LCL is 1:8.

### Claim 9 (depends on 1)

The method of claim 1 wherein the ratio of EBV-CTL:EBV-LCL is 1:16.

### Claim 10 (depends on 1)

The method of claim 1 wherein the ratio of EBV-CTL:EBV-LCL is 1:32.

### Claim 11

A method of antigen specific cell production in a cell culture device with a gas permeable growth surface, comprising:
adding medium and PBMCs at a surface density of at least 1×106 cells/cm2 into the cell culture device, at a medium volume to growth surface ratio of at least 2 ml/cm2; and
stimulating the PBMCs with EBV-LCLs by seeding the EBV-LCLs in said device at a PBMC:EBV-LCL ratio of 40:1; and
allowing a period of time for a population of antigen specific responder T cells to expand in quantity.

### Claim 12 (depends on 11)

The method of claim 11 wherein the period of time is 9 days.

### Claim 13

A method of antigen specific cell production comprising:
Adding PBMCs and a volume of medium into a cell culture device having a growth surface comprised of gas permeable material at a medium volume to growth surface area ratio of at least 2 mL/cm2, wherein the PBMCs reside at a surface density of at least 1×106 cells/cm2 of growth surface and include desired cells that reside at a surface density between 0.5×106 cell/cm2 and 3,900 cells/cm2 of growth surface;
And stimulating the outgrowth of more than one population of desired cells, wherein the more than one population of desired cells are antigen specific T cell populations.

### Claim 14 (depends on 13)

The method of claim 13 wherein the outgrowth of more than one population of desired cells is stimulated by OKT3.
